Direct Healthcare Professional Communication (DHPC) on Giapreza 2.5 mg/ml concentrate for preparation of infusion solution: potentially low fill vials and important information regarding instructions for use
2024.05.27
Active substance: angiotensin II
The company Paion Deutschland GmbH informs that in several hospitals in the USA vials of the medicinal product Giapreza have been detected that are not filled with the required volume. If Giapreza is withdrawn from a low fill vial, the concentration of the medication will not be sufficient and underdosing may occur during use. If a vial contains a volume of less than 1 ml, the company asks users to provide photo documentation as evidence, discard the vial and use a new vial. So far, there have been no reports of low fill vials in the EU.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN